idarubicin hydrochloride - idarubicin hydrochloride injection, solution
fresenius kabi usa, llc - idarubicin hydrochloride (unii: 5vv3mdu5ie) (idarubicin - unii:zrp63d75jw) - idarubicin hydrochloride 1 mg in 1 ml - idarubicin hydrochloride injection, usp in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (aml) in adults. this includes french-american-british (fab) classifications m1 through m7.
idarubicin hydrochloride injection, solution
teva parenteral medicines, inc. - idarubicin hydrochloride (unii: 5vv3mdu5ie) (idarubicin - unii:zrp63d75jw) - idarubicin hydrochloride 1 mg in 1 ml - idarubicin hydrochloride injection in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (aml) in adults. this includes french-american-british (fab) classifications m1 through m7.
idarubicin hydrochloride- idarubicin hydrochloride injection
sandoz inc - idarubicin hydrochloride (unii: 5vv3mdu5ie) (idarubicin - unii:zrp63d75jw) - idarubicin hydrochloride 1 mg in 1 ml - idarubicin hydrochloride injection in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (aml) in adults. this includes french-american-british (fab) classifications m1 through m7.
epirubicin hydrochloride - epirubicin hydrochloride injection, solution
fresenius kabi usa, llc - epirubicin hydrochloride (unii: 22966tx7j5) (epirubicin - unii:3z8479zz5x) - epirubicin hydrochloride 2 mg in 1 ml - epirubicin hydrochloride injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see clinical studies (14.1)]. patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions: cardiomyopathy and/or heart failure, recent myocardial infarction or severe arrhythmias [see warnings and precautions (5.3)] previous treatment with maximum cumulative dose of anthracyclines [see warnings and precautions (5)]. hypersensitivity to epirubicin hydrochloride injection, other anthracyclines, or anthracenediones [see adverse reactions (6.2)]. pregnancy category d. see ‘warnings and precautions’ section. epirubicin hydrochloride can cause fetal harm when administered to a pregnant woman. administration of 0.8 mg/kg/day intravenously of epirubicin to rats (about 0.04 times the maximum recommended single human dose on a body surface area basis) during days 5 to 1
idarubicin hydrochloride injection, solution
hikma pharmaceuticals usa inc. - idarubicin hydrochloride (unii: 5vv3mdu5ie) (idarubicin - unii:zrp63d75jw) - idarubicin hydrochloride 1 mg in 1 ml - idarubicin hydrochloride injection, usp in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (aml) in adults. this includes french-american-british (fab) classifications m1 through m7.
epirubicin hydrochloride- epirubicin hydrochloride injection
impax generics - epirubicin hydrochloride (unii: 22966tx7j5) (epirubicin - unii:3z8479zz5x) - epirubicin hydrochloride 2 mg in 1 ml - epirubicin hydrochloride injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see clinical studies (14.1)]. patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions: cardiomyopathy and/or heart failure, recent myocardial infarction or severe arrhythmias [see warnings and precautions (5.3)] previous treatment with maximum cumulative dose of anthracyclines [see warnings and precautions (5)]. hypersensitivity to epirubicin hydrochloride injection, other anthracyclines, or anthracenediones [see adverse reactions (6.2)]. teratogenic effects pregnancy category d. see ‘warnings and precautions’ section. epirubicin hydrochloride injection can cause fetal harm when administered to a pregnant woman. administration of 0.8 mg/kg/day intravenously of epirubicin to rats (about 0.04 times the maximum recommended single human dose on a body surface area bas
epirubicin hydrochloride- epirubicin hydrochloride injection, solution
sagent pharmaceuticals - epirubicin hydrochloride (unii: 22966tx7j5) (epirubicin - unii:3z8479zz5x) - epirubicin hydrochloride 2 mg in 1 ml - epirubicin hydrochloride injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see clinical studies (14.1)]. patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions: cardiomyopathy and/or heart failure, recent myocardial infarction or severe arrhythmias [see warnings and precautions (5.3)]. previous treatment with maximum cumulative dose of anthracyclines [see warnings and precautions (5)] . hypersensitivity to epirubicin hydrochloride injection, other anthracyclines, or anthracenediones [see adverse reactions (6.2)]. pregnancy category d. see ‘warnings and precautions' section. epirubicin hydrochloride injection can cause fetal harm when administered to a pregnant woman. administration of 0.8 mg/kg/day intravenously of epirubicin to rats (about 0.04 times the maximum recommended single human dose on a body surface area basis) during days 5
epirubicin hydrochloride- epirubicin hydrochloride injection, solution
sandoz inc - epirubicin hydrochloride (unii: 22966tx7j5) (epirubicin - unii:3z8479zz5x) - epirubicin hydrochloride 2 mg in 1 ml - epirubicin hydrochloride injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see clinical studies (14.1) ]. patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions: cardiomyopathy and/or heart failure, recent myocardial infarction or severe arrhythmias [see warnings and precautions (5.3) ] previous treatment with maximum cumulative dose of anthracyclines [see warnings and precautions (5) ]. hypersensitivity to epirubicin hydrochloride injection, other anthracyclines, or anthracenediones [see adverse reactions (6.2) ]. pregnancy category d. see ‘warnings and precautions ’ section. epirubicin hydrochloride injection can cause fetal harm when administered to a pregnant woman. administration of 0.8 mg/kg/day intravenously of epirubicin to rats (about 0.04 times the maximum recommended single human dose on a body surface area basis) during
genepharm mitozatrone hydrochloride mitozantrone hydrochloride 25mg/12.5ml concentrate for injection vial
novotech australia pty ltd - mitozantrone hydrochloride -
genepharm mitozatrone hydrochloride mitozantrone hydrochloride 20mg/10ml concentrate for injection vial
novotech australia pty ltd - mitozantrone hydrochloride -